First Ever Biosimilar Approval in China: Trouble for Roche?
China’s regulator approved a biosimilar version of Roche’s Rituxan this week, the first such drug ever to be given the green light in the country. With numerous other biological copycats…
Address: 20th Floor, NCPC Building (Grand Milea Hotel), No.56 North Tiyu Street, Shijiazhuang, Hebei, P.R.China, Post Code: 050015
Tel: +86 311 85992911
Web: http://www.ncpc.com/
North China Pharmaceutical Group Corp. (NCPC) is a leading pharmaceutical manufacturer in China. NCPC in its early days was one of the key construction projects during the Chinese First Five-Year Plan. After five years of construction beginning in June 1953, operation commenced in June 1958. Being one of the world leading antibiotic producers both in technology and production scale at that time, NCPC has a history of commercial production of antibiotics in China. With 45 years of development, NCPC has been continually growing and taking the lead in China pharmaceutical industry in key economic indexes, ranking as one of the Top 500 Enterprises and the best profit-makers in China. By the end of 2002, the total assets were USD2 billion, and the company was employing 18500 staff. In 2002, NCPC achieved domestic sales revenue USD 700million and export sales USD100million. Sticking to the spirit of ‘Service for Life ‘, NCPC aims to build bright future for all the people.
Antibiotics, Immunosuppressants
China’s regulator approved a biosimilar version of Roche’s Rituxan this week, the first such drug ever to be given the green light in the country. With numerous other biological copycats…
The lowdown on what it takes to be a country manager of a multinational pharma company in some of the world’s most challenging markets. Robert Hall of Ardent Search outlines…
George Lee, vice-president of clinical operations and country leader of PAREXEL in China, discusses the impact of the recent ownership and management changes of the group, the value that PAREXEL…
One of the earliest innovative biotech companies in China, Zensun has developed what its founder Dr Zhou Mingdong calls a rare made-in-China first-in-class therapeutic candidate, the cardiology treatment, Neucardin®. With…
It has been announced by China’s State Council that as of March 1st 2019, the government will reduce the VAT on a “first batch” of 21 rare disease drugs and four…
This is the first in a series of articles examining what it takes to be a country manager of a multinational pharma company in some of the world’s most challenging…
Terns Pharmaceuticals is developing innovative drugs for the treatment of NASH and liver disease. It has established a diverse product pipeline with drug candidates targeting different stages of the disease…
Aditya Bhattacharji manages Eurasia Group‘s healthcare analysis. Together with his colleague Sarah Hassan, a researcher at the company they look at China’s skyrocketing health industry and what to expect from it in the…
Brian Mi, president of IQVIA Greater China, shares IQVIA’s leadership position in China in both the commercial and R&D space, building on both IMS Health and Quintiles’ market positioning in…
Even though China’s pharmaceutical sector remains largely generics-based, the Middle Kingdom’s biotechnology scene has been flourishing in recent years. Now the world’s fastest-growing biopharmaceutical market, China can boast a much-improved…
Dr Xu Ting, founder, chairman and CEO of Alphamab Oncology, shares his expert opinion on the recent regulatory and healthcare reforms in China, the expertise Alphamab Oncology has in protein…
Jack Wang, founder and CEO of Biomobie, shares the inspirational story behind the establishment of the company, the regenerative principle driving the technology of the Bioboostie device, and the innovative…
See our Cookie Privacy Policy Here
